1/13
03:57 pm
bcab
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
1/2
04:54 am
bcab
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
High
Report
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
12/31
09:22 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
12/31
07:00 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)